Oleg Blagosklonov

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11776090/publications.pdf

Version: 2024-02-01

516710 752698 21 996 16 20 g-index citations h-index papers 22 22 22 816 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Imaging aspects and non-surgical interventional treatment in human alveolar echinococcosis. Parasitology International, 2006, 55, S267-S272.	1.3	135
2	Increased Incidence and Characteristics of Alveolar Echinococcosis in Patients With Immunosuppression-Associated Conditions. Clinical Infectious Diseases, 2014, 59, 1095-1104.	5.8	103
3	Should possible recurrence of disease contraindicate liver transplantation in patients with end-stage alveolar echinococcosis? A 20-year follow-up study. Liver Transplantation, 2011, 17, 855-865.	2.4	81
4	The Role of Delayed ¹⁸ F-FDG PET Imaging in the Follow-up of Patients with Alveolar Echinococcosis. Journal of Nuclear Medicine, 2013, 54, 358-363.	5.0	77
5	Utility of 18F-fluoro-dexoxyglucose positron emission tomography for the diagnosis of polymyalgia rheumatica: a controlled study. Rheumatology, 2016, 55, 1452-1457.	1.9	75
6	Innovation in hepatic alveolar echinococcosis imaging: best use of old tools, and necessary evaluation of new ones. Parasite, 2014, 21, 74.	2.0	70
7	Alveolar echinococcosis: correlation between hepatic MRI findings and FDG-PET/CT metabolic activity. Abdominal Imaging, 2015, 40, 56-63.	2.0	64
8	TGF- \hat{l}^2 and TGF- \hat{l}^2 /Smad Signaling in the Interactions between Echinococcus multilocularis and Its Hosts. PLoS ONE, 2013, 8, e55379.	2.5	57
9	30-yr course and favorable outcome of alveolar echinococcosis despite multiple metastatic organ involvement in a non-immune suppressed patient. Annals of Clinical Microbiology and Antimicrobials, 2013, 12, 1.	3.8	54
10	Current interventional strategy for the treatment of hepatic alveolar echinococcosis. Expert Review of Anti-Infective Therapy, 2016, 14, 1179-1194.	4.4	51
11	<i>Echinococcus</i> metacestode: in search of viability markers. Parasite, 2014, 21, 63.	2.0	47
12	Transcriptional Profiles of Cytokine/Chemokine Factors of Immune Cell-Homing to the Parasitic Lesions: A Comprehensive One-Year Course Study in the Liver of E. multilocularis-Infected Mice. PLoS ONE, 2014, 9, e91638.	2.5	46
13	Deletion of Fibrinogen-like Protein 2 (FGL-2), a Novel CD4+ CD25+ Treg Effector Molecule, Leads to Improved Control of Echinococcus multilocularis Infection in Mice. PLoS Neglected Tropical Diseases, 2015, 9, e0003755.	3.0	45
14	Circulating cell-free DNA in patients with alveolar echinococcosis. Molecular and Biochemical Parasitology, 2018, 222, 14-20.	1,1	20
15	Positron emission tomography: The ideal tool in polymyalgia rheumatica?. Joint Bone Spine, 2014, 81, 381-383.	1.6	18
16	AE hepatic lesions: correlation between calcifications at CT and FDG-PET/CT metabolic activity. Infection, 2019, 47, 955-960.	4.7	13
17	Development of a specific tracer for metabolic imaging of alveolar echinococcosis: A preclinical study. , 2014, 2014, 5587-90.		8
18	Hints for control of infection in unique extrahepatic vertebral alveolar echinococcosis. Infection, 2017, 45, 365-368.	4.7	8

#	Article	IF	CITATIONS
19	Involvement of pubic symphysis in polymyalgia rheumatica: 18-FDG PET/CT evaluation. Joint Bone Spine, 2017, 84, 635-636.	1.6	3
20	Diagnostic de l'échinococcose alvéolaire. Revue Francophone Des Laboratoires, 2014, 2014, 77-87.	0.0	2
21	Atteinte de la symphyse pubienne dans la pseudopolyarthrite rhizoméliqueÂ: évaluation par un 18-FDG-PET/CT. Revue Du Rhumatisme (Edition Francaise), 2018, 85, 405-406.	0.0	0